B. Fisher

发表

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

E. Eisenhauer, K. Gelmon, H. Hirte, 2004, Investigational New Drugs.

A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer.

L. Seymour, D. Jonker, M. Vincent, 2006, European journal of cancer.

Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study.

E. Eisenhauer, J. Dancey, G. Batist, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).

A. Oza, K. Swenerton, L. Seymour, 2010, Gynecologic oncology.

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first‐line therapy in patients with advanced nonsmall cell lung carcinoma

E. Eisenhauer, J. Dancey, F. Shepherd, 2001, Cancer.

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.

E. Eisenhauer, J. Dancey, C. Butts, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers.

E. Eisenhauer, K. Gelmon, H. Hirte, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study.

E. Eisenhauer, A. Oza, I. Vergote, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials Group.

E. Eisenhauer, K. Swenerton, G. Batist, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.

L. Seymour, H. Hirte, D. Lebwohl, 2002, Gynecologic oncology.

Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours

A. Oza, L. Seymour, M. Moore, 2005, Cancer Chemotherapy and Pharmacology.

A phase I/II study of paclitaxel (TAXOL) and concurrent radiotherapy in advanced nonsmall cell lung cancer.

E. Eisenhauer, K. Gelmon, P. Kirkbride, 1997, International journal of radiation oncology, biology, physics.

Phase II trial of the multi-targeted antifolate LY231514 (MTA) as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC)

E. Eisenhauer, J. Dancey, C. Butts, 1997 .

Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)

E. Eisenhauer, S. Hotte, J. Knox, 2007, Investigational New Drugs.

Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.

E. Eisenhauer, K. Gelmon, A. Tolcher, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group.

E. Eisenhauer, F. Shepherd, M. Crump, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours

E. Eisenhauer, L. Siu, W. Walsh, 2007, Investigational New Drugs.

Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.

E. Eisenhauer, K. Gelmon, A. Tolcher, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of paclitaxel (TaxolQ) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer*

E. Eisenhauer, F. Shepherd, M. Crump, 1996 .

Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer

E. Eisenhauer, Y. Cormier, J. Latreille, 1995, Investigational New Drugs.